Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
Fernando Bril, Kenneth Cusi
Diabetes Care (2017) Vol. 40, Iss. 3, pp. 419-430
Open Access | Times Cited: 312

Showing 1-25 of 312 citing articles:

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi, Pegah Golabi, Leyla de Avila, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 4, pp. 793-801
Closed Access | Times Cited: 1741
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1110
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan, Hans‐Ulrich Häring, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 4, pp. 313-324
Closed Access | Times Cited: 731
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 661
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 628
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Mario Masarone, Valerio Rosato, Marcello Dallio, et al.
Oxidative Medicine and Cellular Longevity (2018) Vol. 2018, pp. 1-14
Open Access | Times Cited: 553
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Alessandro Mantovani, Christopher D. Byrne, Enzo Bonora, et al.
Diabetes Care (2018) Vol. 41, Iss. 2, pp. 372-382
Open Access | Times Cited: 490
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Giovanni Targher, Amedeo Lonardo, Christopher D. Byrne
Nature Reviews Endocrinology (2017) Vol. 14, Iss. 2, pp. 99-114
Closed Access | Times Cited: 357
Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery
Roy Taylor, Ahmad Al-Mrabeh, Sviatlana Zhyzhneuskaya, et al.
Cell Metabolism (2018) Vol. 28, Iss. 4, pp. 547-556.e3
Open Access | Times Cited: 353
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies
Nishanth E. Sunny, Fernando Bril, Kenneth Cusi
Trends in Endocrinology and Metabolism (2016) Vol. 28, Iss. 4, pp. 250-260
Closed Access | Times Cited: 271
Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial
Shaminie J. Athinarayanan, Rebecca N. Adams, Sarah J. Hallberg, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 260
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Sven Francque, Gyöngyi Szabó, Manal F. Abdelmalek, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 1, pp. 24-39
Closed Access | Times Cited: 239
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 235
Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Lili Niu, Philipp E. Geyer, Nicolai J. Wewer Albrechtsen, et al.
Molecular Systems Biology (2019) Vol. 15, Iss. 3
Open Access | Times Cited: 229
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Karen D. Corbin, Kimberly A. Driscoll, Richard E. Pratley, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 629-663
Open Access | Times Cited: 203
Hepatic Insulin Clearance: Mechanism and Physiology
Sonia M. Najjar, Germán Perdomo
Physiology (2019) Vol. 34, Iss. 3, pp. 198-215
Open Access | Times Cited: 201
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
Fernando Bril, Srilaxmi Kalavalapalli, Virginia Clark, et al.
Clinical Gastroenterology and Hepatology (2017) Vol. 16, Iss. 4, pp. 558-566.e2
Closed Access | Times Cited: 181
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
Kenneth Cusi, Fernando Bril, Diana Barb, et al.
Diabetes Obesity and Metabolism (2018) Vol. 21, Iss. 4, pp. 812-821
Closed Access | Times Cited: 164
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
Fernando Bril, Michael J. McPhaul, Michael P. Caulfield, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 290-297
Open Access | Times Cited: 148
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 141
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
Diana Barb, Enrico Repetto, Michael Edward Stokes, et al.
Obesity (2021) Vol. 29, Iss. 11, pp. 1950-1960
Open Access | Times Cited: 112
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, Javed Butler, George L. Bakris, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 2, pp. 108389-108389
Open Access | Times Cited: 39
Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation
Cédric Peleman, Sven Francque, Tom Vanden Berghe
EBioMedicine (2024) Vol. 102, pp. 105088-105088
Open Access | Times Cited: 15
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, John E. Anderson, George L. Bakris, et al.
Metabolism (2024) Vol. 159, pp. 155931-155931
Open Access | Times Cited: 14
Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice
Weiting Hu, Wenyu Gong, Fan Yang, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113937-113937
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top